Skip to Content

Agilent Technologies Inc - Stock Quote A

Rating as of

Morningstar's Agilent Technologies Inc Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Agilent Turns In Solid Q1 With Guidance About as Expected; Shares Still Moderately Rich

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Wide-moat Agilent released strong first-quarter results and management increased its fiscal 2022 outlook slightly on the top and bottom lines. Our profit and cash flow estimates for this year are in line with and higher, respectively, than management's new guidance, so at first glance, we do not anticipate changing our $107 fair value estimate. The shares still appear moderately rich to us.

Read Full Analysis

Agilent Technologies Inc's Company Profile

Business Description

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.

5301 Stevens Creek Boulevard
Santa Clara, CA, 95051
T +1 800 227-9770
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Jan 31, 2022
Fiscal Year End Oct 31, 2022
Stock Type Classic Growth
Employees 17,200

Agilent Technologies Inc's Related Articles & News